2018
DOI: 10.1159/000490038
|View full text |Cite
|
Sign up to set email alerts
|

Tumour Expression of Histone Deacetylases in Uveal Melanoma

Abstract: Purpose: To determine the expression of histone deacetylase enzymes in uveal melanoma tumour cells. Procedures: This is an observational immunohistochemical study of 16 formalin-fixed, paraffin-embedded eyes enucleated for uveal melanoma between January 2001 and March 2002. Haematoxylin and eosin paraffin sections were reviewed for histopathological parameters according to the American Joint Committee on Cancer 7th edition. Sections were then immunohistochemically stained for histone deacetylases 1, 2, 3, 4 an… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
18
0

Year Published

2020
2020
2022
2022

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 13 publications
(22 citation statements)
references
References 42 publications
(48 reference statements)
3
18
0
Order By: Relevance
“…The use of histone deacetylases inhibitors proved to reverse H2A hyperubiquitination, inducing cell differentiation and inhibiting tumor growth ( 175 ). Indeed, the nuclear expression of several histone deacetylases has been found in UMs, confirming the role of this epigenetic alteration as a potential therapeutic target ( 177 ).…”
Section: Genetic and Epigenetic Features In Uveal Melanomamentioning
confidence: 73%
“…The use of histone deacetylases inhibitors proved to reverse H2A hyperubiquitination, inducing cell differentiation and inhibiting tumor growth ( 175 ). Indeed, the nuclear expression of several histone deacetylases has been found in UMs, confirming the role of this epigenetic alteration as a potential therapeutic target ( 177 ).…”
Section: Genetic and Epigenetic Features In Uveal Melanomamentioning
confidence: 73%
“…HDAC IHC expression has been described in several tumor types, being associated with important clinicopathological parameters, including patients’ prognosis [ 18 , 19 , 20 , 22 , 24 , 25 , 26 ]. Information on HDAC IHC expression in UMs remains scarce, as the available data so far are limited to one recent study conducted on 16 UM specimens without, however, any attempt to correlate it with patients’ clinical information [ 17 ]. Moreover, Souri et al, in two recent studies, report the expression of HDAC-1, -3, -4, -8 using gene expression profiling [ 15 , 16 ].…”
Section: Discussionmentioning
confidence: 99%
“…Apart from the increasing research of HDACIs in UMs, there is, to the best of our knowledge, to date, no comprehensive available information regarding the clinical significance of HDACs expression. Souri et al recently described the expression of HDACs using gene expression profiling [ 15 , 16 ], while only one recent observational immunohistochemical study exists investigating the expression of HDACs in 16 UM cases [ 17 ]. In view of the above considerations, the present study aims to assess the immunohistochemical expression of several members of HDAC protein family classes I and II (a,b), namely HDAC-1, -2, -4, and -6, in UM specimens, in association with clinicopathological parameters as well as patients’ overall survival (OS) and disease-free survival (DFS).…”
Section: Introductionmentioning
confidence: 99%
“…Then, with the aim to deeply investigate the biological properties of the four most promising hydroxamic derivatives, we performed in vitro assays on isolated Class I enzymes (HDACs 1,3,8) and Class II HDAC6. Considering the expression of histone deacetylases in UM 23 and the potential therapeutic role of HDACIs in this tumour 5 , the same compounds were selected for further tests on UM cell lines. Finally, docking studies were performed to investigate their binding mode.…”
Section: Introductionmentioning
confidence: 99%